Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. (Q45993626)

18 December 2017

title

Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. (English)

1 reference

18 December 2017

1 reference

1 reference

J Blacher

1

0 references

Philippe Amouyel

object named as

P Amouyel

4

0 references

author name string

A Evans

2

1 reference

18 December 2017

D Arveiler

3

1 reference

18 December 2017

J Ferrières

5

1 reference

18 December 2017

A Bingham

6

1 reference

18 December 2017

J Yarnell

7

1 reference

18 December 2017

B Haas

8

1 reference

18 December 2017

M Montaye

9

1 reference

18 December 2017

J-B Ruidavets

10

1 reference

18 December 2017

P Ducimetière

11

1 reference

18 December 2017

PRIME Study Group

12

1 reference

18 December 2017

publication date

1 January 2010

1 reference

18 December 2017

Journal of Human Hypertension

published in

1 reference

18 December 2017

volume

24

1 reference

18 December 2017

issue

1

1 reference

18 December 2017

page(s)

19-26

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1038/jhh.2009.34

exact match

0 references

cites work

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Survival in treated hypertension: follow up study after two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Diuretic therapy for hypertension and the risk of primary cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

Clinical epidemiology, clinical care, and the public's health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.34

7 January 2021

Identifiers

DOI

10.1038/JHH.2009.34

1 reference

18 December 2017

Dimensions Publication ID

0 references

1 reference

18 December 2017